Standout Papers

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis 2022 2026 2023 2024114
  1. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis (2022)
    Eric L. Simpson, Kim Papp et al. JAMA Dermatology

Immediate Impact

6 from Science/Nature 64 standout
Sub-graph 1 of 23

Citing Papers

A vision–language foundation model for precision oncology
2025 StandoutNature
Atopic dermatitis
2025 Standout
5 intermediate papers

Works of Albert S. Chiou being referenced

Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study
2023
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
2022 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Albert S. Chiou 267 134 92 208 148 46 794
Cornelia Hofmann 412 37 54 81 70 49 934
María Dolores Boyano 86 34 53 536 113 56 973
Mingxiang Lin 76 99 219 96 13 38 681
Eckart Köttgen 40 70 22 425 53 32 744
Bhavin Adhyaru 106 7 12 181 287 26 861
Athula Herath 121 110 35 358 35 18 823
Robert De Jager 17 75 54 459 91 51 974
Guihua Jin 30 18 84 409 104 35 884
Ilaria Cicalini 19 33 90 561 26 45 902
Michihiko Waki 69 43 19 413 73 37 741

All Works

Loading papers...

Rankless by CCL
2026